Arcadia Biosciences Inc

NASDAQ RKDA

Data sourced from

and

Daily

Download Data

Arcadia Biosciences Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024

Arcadia Biosciences Inc Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Arcadia Biosciences Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Arcadia Biosciences Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is NA on June 03, 2024, which is NA below the current Enterprise Value to EBITDA (EV/EBITDA).
Arcadia Biosciences Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is NA.

NASDAQ: RKDA

Arcadia Biosciences Inc

CEO	Ms. Pamela Haley
IPO Date	May 15, 2015
Location	United States
Headquarters	202 Cousteau Place, Davis, CA, United States, 95618
Employees	21
Sector	Consumer Defensive
Industry	Packaged foods

Description

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

Key trends